Description du projet
Nouveau biomarqueur de l’ischémie cardiaque
La restriction de l’apport sanguin au cœur provoque une ischémie myocardique et peut entraîner des lésions tissulaires, ce qui a un impact significatif sur la capacité du cœur à pomper le sang. Il n’existe cependant pas de biomarqueurs pour détecter l’ischémie cardiaque à un stade précoce. Le projet AGLYC, financé par l’UE, a mis au point un dispositif de diagnostic in vitro qui mesure les taux sanguins d’apolipoprotéine J glycosylée comme biomarqueur de l’ischémie cardiaque. Le test repose sur le fait que, chez les patients atteints d’infarctus aigu du myocarde, le schéma de glycosylation de l’apolipoprotéine J change. La mise en œuvre du test dans la pratique clinique offrira aux médecins la possibilité de détecter l’ischémie dans les 30 minutes suivant son apparition et de commencer le traitement approprié.
Objectif
Cardiovascular diseases (CVD) are the leading cause of death/morbidity across the globe, accounting for 31% of all deaths in 2015.
Early detection of ischemia (restriction in blood supply to tissues, causing oxygen shortage) is essential to prevent the progression of heart damage, but right now, we don’t have any biomarkers for the early detection of cardiac ischemia. In fact, almost 90% of the available in vitro diagnostic (IVD) methods are based on the quantification of markers of necrosis, an advanced stage of organ damage. Obviously, these methods are useless for the early detection of ischemic damage.
AGLYC is an IVD device based on the rapid quantification circulating plasma Apo J-Glyc levels as a novel biomarker for the diagnosis, prognosis and risk stratification of ischemia and ischemic tissue damage. AGLYC demonstrates a 97% sensitivity in detecting the presence of cardiac ischemia; market state of the art is 39%. It also detects ischemic damage at an early and reversible phase (30 min after ischemia onset); state of the art can only detect ischemia 6 hrs after its onset when tissue damage is irreversible. We are currently at TRL6 having the competitive advantages of high sensitivity, early detection and cost effectiveness.
The Global IVD market accounted for $61,103M in 2016 and is estimated to reach $84,647M by 2023, growing at a CAGR of 4.6% from 2017-2023. We have estimated a lab-based target market of >70M patients (USA+5EU) and a Point of Care (POC) target market of >36M patients (USA+5EU). Our main business model will be a sublicense model: a lab-based test will be developed and sublicensed to either a medical device company (like MedTech) or to a pharmaceutical company for the co-development and commercialization of the POC device. GlyCardial Diagnostics, S.L. is a small company of 4 (3 women, 1 man) but with the successful completion of the SMEI Phase 1 and 2 we estimate an EBITDA of around €19M, creating 10 new jobs by 2024.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
08028 BARCELONA
Espagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.